HHS Invites Public Feedback on Enhancing Access to Islet Cell Treatments from Deceased Donors
-
By
-
Assistant Secretary for Public Affairs (ASPA)
-
September 23, 2026
Clinical Report: HHS Invites Public Feedback on Islet Cell Treatments
Overview
The HHS has issued a Request for Information (RFI) to gather public feedback on regulatory changes regarding access to deceased donor islet cells for type 1 diabetes treatment.
Background
Type 1 diabetes is a significant global health issue, affecting millions and often requiring lifelong insulin therapy. Deceased donor islet cell transplantation is being evaluated as a potential alternative therapy. However, current FDA regulations may pose barriers to accessing these therapies, prompting HHS to seek public input on possible regulatory adjustments.
Data Highlights
No numerical data or trial data is provided in the article.
Key Findings
- The FDA currently regulates deceased donor islet cells as biological products.
- HHS is evaluating whether these cells should be classified as organs for transplantation.
- The RFI seeks feedback on barriers to patient access under current FDA regulations.
- HHS emphasizes maintaining stringent safety and quality requirements in any new regulatory framework.
- Interested parties can submit comments until November 8, 2026.
Clinical Implications
Healthcare professionals should be aware of the ongoing public feedback process regarding access to islet cell transplantation.
Conclusion
The HHS's RFI is a measure to gather public input on improving access to islet cell therapies for type 1 diabetes while ensuring patient safety.
Related Resources & Content
- HHS Seeks Public Input to Improve Access to Deceased Donor Islet Cell Treatments | HHS.gov, 2026 -- HHS Invites Public Feedback on Enhancing Access to Islet Cell Treatments
- Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes—2026 | Diabetes Care | American Diabetes Association, 2026 -- Standards of Care in Diabetes
- The Journal of Clinical Endocrinology & Metabolism — Utilizing Autologous Cells to Reverse Diabetes: Approaching the Ideal Solution
- the analytical scientist — Stimulating and Sensing Insulin Secretion
- Frontiers in Immunology — Impact of donor stress-induced hyperglycemia on early graft outcomes in simultaneous pancreas-kidney transplantation: a retrospective cohort study
- MDSpire News — Allogeneic Islet Transplant Shows Promise Without Immunosuppression
- HHS Seeks Public Input to Improve Access to Deceased Donor Islet Cell Treatments | HHS.gov
- https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2025.15091/pdf
- 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes—2026 | Diabetes Care | American Diabetes Association
Based on findings from:
HHS Seeks Public Input to Improve Access to Deceased Donor Islet Cell Treatments
Assistant Secretary for Public Affairs (ASPA). United States Department Of Health And Human Services, 2026.
https://www.hhs.gov/press-room/hhs-seeks-public-input-deceased-donor-islet-cell-treatments.html
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
